Premium
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs
Author(s) -
Iurlo Alessandra,
Cattaneo Daniele,
Malato Alessandra,
Accurso Vincenzo,
Annunziata Mario,
Gozzini Antonella,
Scortechini Anna Rita,
Bucelli Cristina,
Scalzulli Emilia,
Attolico Imma,
Maggi Alessandro,
Martino Bruno,
Caocci Giovanni,
Abruzzese Elisabetta,
Pregno Patrizia,
Luciano Luigiana,
Breccia Massimo
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25908
Subject(s) - ponatinib , myeloid leukemia , medicine , leukemia , oncology , pharmacology , cancer research , dasatinib , imatinib
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom